Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study

B Haber; GR Foster; K Agarwal; ME Cramp; S Moreea; S Barclay; J Collier; AS Brown; SD Ryder; A Ustianowski; D Forton; R Fox; F Gordon; W Rosenberg; DJ Mutimer; J Du; CL Gilbert; M Robertson; E Barr

doi:10.1016/s0016-5085(17)33584-9

Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study

B Haber
, GR Foster
, K Agarwal
, ME Cramp
, S Moreea
, S Barclay
, J Collier
, AS Brown
, SD Ryder
, A Ustianowski
, D Forton
, R Fox
, F Gordon
, W Rosenberg
, DJ Mutimer
, J Du
, CL Gilbert
, M Robertson
, E Barr

Peninsula Medical School

Research output: Contribution to conference › Conference paper (not formally published) › peer-review

Original language	English
DOIs	https://doi.org/10.1016/s0016-5085(17)33584-9
Publication status	Published - Apr 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/s0016-5085(17)33584-9

Cite this

Haber, B., Foster, GR., Agarwal, K., Cramp, ME., Moreea, S., Barclay, S., Collier, J., Brown, AS., Ryder, SD., Ustianowski, A., Forton, D., Fox, R., Gordon, F., Rosenberg, W., Mutimer, DJ., Du, J., Gilbert, CL., Robertson, M., & Barr, E. (2017). Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study. https://doi.org/10.1016/s0016-5085(17)33584-9

@conference{adad2f86ffab47c29280b6124e2e5fcb,

title = "Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study",

author = "B Haber and GR Foster and K Agarwal and ME Cramp and S Moreea and S Barclay and J Collier and AS Brown and SD Ryder and A Ustianowski and D Forton and R Fox and F Gordon and W Rosenberg and DJ Mutimer and J Du and CL Gilbert and M Robertson and E Barr",

year = "2017",

month = apr,

doi = "10.1016/s0016-5085(17)33584-9",

language = "English",

}

Haber, B, Foster, GR, Agarwal, K, Cramp, ME, Moreea, S, Barclay, S, Collier, J, Brown, AS, Ryder, SD, Ustianowski, A, Forton, D, Fox, R, Gordon, F, Rosenberg, W, Mutimer, DJ, Du, J, Gilbert, CL, Robertson, M & Barr, E 2017, 'Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study'. https://doi.org/10.1016/s0016-5085(17)33584-9

TY - CONF

T1 - Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study

AU - Haber, B

AU - Foster, GR

AU - Agarwal, K

AU - Cramp, ME

AU - Moreea, S

AU - Barclay, S

AU - Collier, J

AU - Brown, AS

AU - Ryder, SD

AU - Ustianowski, A

AU - Forton, D

AU - Fox, R

AU - Gordon, F

AU - Rosenberg, W

AU - Mutimer, DJ

AU - Du, J

AU - Gilbert, CL

AU - Robertson, M

AU - Barr, E

PY - 2017/4

Y1 - 2017/4

U2 - 10.1016/s0016-5085(17)33584-9

DO - 10.1016/s0016-5085(17)33584-9

M3 - Conference paper (not formally published)

ER -